Schering-Plough Corporation
2000 Galloping Hill Road Kenilworth, NJ 07033
Phone: (908) 298-4000
Web Site: www.schering-plough.com
Industry: Drugs Sector: Healthcare
Employees: 32,600
Stock Symbol: SGP

Business Summary Schering-Plough Corporation was incorporated in New York in 1928 and New Jersey in 1935. The Company is a science-based health care company with prescription, consumer and animal health products. Through internal research and collaborations with business partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients, customers and shareholders that it serves around the world. Currently, Schering-Plough has three reportable segments: Prescription Pharmaceuticals, Consumer Health Care and Animal Health. The Prescription Pharmaceuticals segment discovers, develops, manufactures and markets human pharmaceutical products. Within the Prescription Pharmaceutical segment there are three customer groups: Primary Care, Specialty Care and the Cholesterol Franchise. Products in this segment include: Primary Care- Allergy/ Respiratory, Antibiotics, Dermatologicals and Other Disorders; Specialty Care- Anti-Virals, Anti-Inflammatories, Oncology, Acute Coronary Care and Other Disorders; Cholesterol Franchise- ZETIA and VYTORIN. The Consumer Health Care segment develops, manufactures and markets OTC, foot care and sun care products. Products in this segment include: Over-the-Counter Products, Foot Care and Sun Care. The Animal Health segment discovers, develops, manufactures and markets animal health products. Products in this segment include: Livestock Products, Poultry Products, Companion Animal Products and Aquaculture Products. Schering-Plough's research activities are aimed at discovering and developing new prescription products and enhancements to existing prescription products of medical and commercial significance. Schering-Plough's subsidiaries own a number of patents and patent applications, both in the U.S. and abroad. Patents and patent applications relating to Schering-Plough's products, including VYTORIN, ZETIA, REMICADE, NASONEX INTRON A, PEG-INTRON, TEMODAR and CLARINEX, are of material importance to Schering-Plough. Schering-Plough sells all products under trademarks that also are material in the aggregate to its business and financial results. Prescription drugs are introduced and made known to physicians, pharmacists, hospitals, managed care organizations and buying groups by trained professional sales representatives, and are sold to hospitals, certain managed care organizations, wholesale distributors and retail pharmacists. Prescription products are also introduced and made known through journal advertising, direct mail advertising, the distribution of samples to physicians and through television, radio, internet, print and other advertising media. Each of the Company's business segments is subject to regulation in multiple jurisdictions. Raw materials essential to Schering-Plough are available in adequate quantities from a number of potential suppliers. Energy is expected to be available to Schering-Plough in sufficient quantities to meet operating requirements. There were approximately 32,600 people employed by Schering-Plough as of December 31, 2005. Officers: Fred Hassan , CEO